Market Overview

UPDATE: Credit Suisse Upgrades Dr. Reddy's Laboratories Limited to Outperform on Metropol Market Share

Related RDY
Benzinga's Volume Movers
Dr. Reddy's Launches Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

Credit Suisse raised its rating on Dr. Reddy's Laboratories Limited (NYSE: RDY) from Neutral to Outperform.

Credit Suisse said, "Our positive stance on Dr. Reddy's is driven by a strong pick-up in US sales in the coming quarters. Dr. Reddy's market share on Metoprolol has increased to 15% vs. expectation of 8-10%. Metoprolol market size is large at US$450 mn and is a high-margin product. Our interactions with Intas and Cadila suggested that Metoprolol approval for them is not a near-term event and therefore for at least the next six months Dr. Reddy's should continue to enjoy a high market share on Metoprolol."

Dr. Reddy's Laboratories Limited closed at $34.25 on Wednesday.

Latest Ratings for RDY

Feb 2013Bank of AmericaDowngradesBuyNeutral
Dec 2012Credit SuisseUpgradesNeutralOutperform
Jun 2012Anand RathiUpgradesHoldBuy

View More Analyst Ratings for RDY
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (RDY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters